Relief Therapeutics Holding Valuation

Is V6M1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of V6M1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate V6M1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate V6M1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for V6M1?

Key metric: As V6M1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for V6M1. This is calculated by dividing V6M1's market cap by their current revenue.
What is V6M1's PS Ratio?
PS Ratio	3.4x
Sales	CHF 5.86m
Market Cap	CHF 20.06m

V6M1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	-0.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does V6M1's PS Ratio compare to its peers?

The above table shows the PS ratio for V6M1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.1x
2INV 2invest	8.2x	n/a	€63.8m
MDG1 Medigene	3x	16.1%	€22.6m
CNW co.don	0.7x	n/a	€6.5m
HPHA Heidelberg Pharma	12.3x	16.6%	€103.9m
V6M1 Relief Therapeutics Holding	3.4x	n/a	€20.1m

Price-To-Sales vs Peers: V6M1 is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (12.7x).

Price to Sales Ratio vs Industry

How does V6M1's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: V6M1 is good value based on its Price-To-Sales Ratio (3.4x) compared to the European Biotechs industry average (10.6x).

Price to Sales Ratio vs Fair Ratio

What is V6M1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

V6M1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate V6M1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

-7.1%

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

-6.2%

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

0.3%

-0.4%